
Bridget E. Bunner
Examiner (ID: 13118, Phone: (571)272-0881 , Office: P/1647 )
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647, 1644 |
| Total Applications | 1451 |
| Issued Applications | 718 |
| Pending Applications | 165 |
| Abandoned Applications | 598 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 6494254
[patent_doc_number] => 20100009934
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-01-14
[patent_title] => 'BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS'
[patent_app_type] => utility
[patent_app_number] => 12/480034
[patent_app_country] => US
[patent_app_date] => 2009-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 24520
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0009/20100009934.pdf
[firstpage_image] =>[orig_patent_app_number] => 12480034
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/480034 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | Jun 7, 2009 | Abandoned |
Array
(
[id] => 6229863
[patent_doc_number] => 20100184091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-07-22
[patent_title] => 'Method for determining MIF content'
[patent_app_type] => utility
[patent_app_number] => 12/477889
[patent_app_country] => US
[patent_app_date] => 2009-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 31349
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0184/20100184091.pdf
[firstpage_image] =>[orig_patent_app_number] => 12477889
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/477889 | Method for determining MIF content | Jun 2, 2009 | Abandoned |
Array
(
[id] => 8293986
[patent_doc_number] => 08221765
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-07-17
[patent_title] => 'Multivalent fibronectin based scaffold domain proteins'
[patent_app_type] => utility
[patent_app_number] => 12/470989
[patent_app_country] => US
[patent_app_date] => 2009-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 63
[patent_no_of_words] => 40316
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 234
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12470989
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/470989 | Multivalent fibronectin based scaffold domain proteins | May 21, 2009 | Issued |
Array
(
[id] => 6358893
[patent_doc_number] => 20100087358
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-04-08
[patent_title] => 'NOTCH mutations leading to increased receptor signaling'
[patent_app_type] => utility
[patent_app_number] => 12/453833
[patent_app_country] => US
[patent_app_date] => 2009-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 11186
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20100087358.pdf
[firstpage_image] =>[orig_patent_app_number] => 12453833
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/453833 | NOTCH mutations leading to increased receptor signaling | May 21, 2009 | Issued |
Array
(
[id] => 5304118
[patent_doc_number] => 20090298770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-03
[patent_title] => 'MAMMALIAN RELAXIN RECEPTORS'
[patent_app_type] => utility
[patent_app_number] => 12/426771
[patent_app_country] => US
[patent_app_date] => 2009-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 15641
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0298/20090298770.pdf
[firstpage_image] =>[orig_patent_app_number] => 12426771
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/426771 | MAMMALIAN RELAXIN RECEPTORS | Apr 19, 2009 | Abandoned |
Array
(
[id] => 5552287
[patent_doc_number] => 20090286273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-19
[patent_title] => 'USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET'
[patent_app_type] => utility
[patent_app_number] => 12/424962
[patent_app_country] => US
[patent_app_date] => 2009-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 7259
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0286/20090286273.pdf
[firstpage_image] =>[orig_patent_app_number] => 12424962
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/424962 | Neuregulin-β isoform | Apr 15, 2009 | Issued |
Array
(
[id] => 6087865
[patent_doc_number] => 20110217294
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-09-08
[patent_title] => 'COMBINATION OF HGF INHIBITOR AND HEDGEHOG INHIBITOR TO TREAT CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/935264
[patent_app_country] => US
[patent_app_date] => 2009-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 10703
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0217/20110217294.pdf
[firstpage_image] =>[orig_patent_app_number] => 12935264
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/935264 | COMBINATION OF HGF INHIBITOR AND HEDGEHOG INHIBITOR TO TREAT CANCER | Apr 8, 2009 | Abandoned |
Array
(
[id] => 5945113
[patent_doc_number] => 20110105733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-05-05
[patent_title] => 'SINGLE VARIABLE DOMAINS AGAINST THE NOTCH PATHWAYS'
[patent_app_type] => utility
[patent_app_number] => 12/934766
[patent_app_country] => US
[patent_app_date] => 2009-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 90474
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0105/20110105733.pdf
[firstpage_image] =>[orig_patent_app_number] => 12934766
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/934766 | Single variable domains against notch pathway members | Apr 6, 2009 | Issued |
Array
(
[id] => 5928896
[patent_doc_number] => 20110038855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-17
[patent_title] => 'TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL'
[patent_app_type] => utility
[patent_app_number] => 12/417487
[patent_app_country] => US
[patent_app_date] => 2009-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 36612
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0038/20110038855.pdf
[firstpage_image] =>[orig_patent_app_number] => 12417487
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/417487 | TRAIL AND METHODS OF MODULATING T CELL ACTIVITY AND ADAPTIVE IMMUNE RESPONSES USING TRAIL | Apr 1, 2009 | Abandoned |
Array
(
[id] => 6070044
[patent_doc_number] => 20110044894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-02-24
[patent_title] => 'Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof'
[patent_app_type] => utility
[patent_app_number] => 12/810006
[patent_app_country] => US
[patent_app_date] => 2009-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 29218
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0044/20110044894.pdf
[firstpage_image] =>[orig_patent_app_number] => 12810006
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/810006 | Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof | Mar 25, 2009 | Abandoned |
Array
(
[id] => 6135223
[patent_doc_number] => 20110008891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-01-13
[patent_title] => 'PARTIAL PEPTIDE OF LACRITIN'
[patent_app_type] => utility
[patent_app_number] => 12/922084
[patent_app_country] => US
[patent_app_date] => 2009-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7176
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0008/20110008891.pdf
[firstpage_image] =>[orig_patent_app_number] => 12922084
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/922084 | Partial peptide of lacritin | Mar 18, 2009 | Issued |
Array
(
[id] => 122088
[patent_doc_number] => 07704499
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-04-27
[patent_title] => 'Antibodies against a peptide epitope of apoliporotein B'
[patent_app_type] => utility
[patent_app_number] => 12/394857
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 11473
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/704/07704499.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394857
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394857 | Antibodies against a peptide epitope of apoliporotein B | Feb 26, 2009 | Issued |
Array
(
[id] => 5315528
[patent_doc_number] => 20090280126
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-12
[patent_title] => 'PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS'
[patent_app_type] => utility
[patent_app_number] => 12/394787
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 11481
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0280/20090280126.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394787
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394787 | Antibodies against a peptide epitope of apolipoprotein B | Feb 26, 2009 | Issued |
Array
(
[id] => 5479566
[patent_doc_number] => 20090202523
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-13
[patent_title] => 'ANTIBODIES AGAINST A PEPTIDE EPITOPE OF APOLIPOROTEIN B'
[patent_app_type] => utility
[patent_app_number] => 12/394919
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 11477
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0202/20090202523.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394919
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394919 | Antibodies against a peptide epitope of apoliprotein B | Feb 26, 2009 | Issued |
Array
(
[id] => 5385230
[patent_doc_number] => 20090226475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-09-10
[patent_title] => 'PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS'
[patent_app_type] => utility
[patent_app_number] => 12/394744
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 11484
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0226/20090226475.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394744
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394744 | PEPTIDE-BASED IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS | Feb 26, 2009 | Abandoned |
Array
(
[id] => 7522721
[patent_doc_number] => 08025876
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-09-27
[patent_title] => 'Antibodies against a peptide epitope of apolipoprotein B'
[patent_app_type] => utility
[patent_app_number] => 12/394827
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 11475
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/025/08025876.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394827
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394827 | Antibodies against a peptide epitope of apolipoprotein B | Feb 26, 2009 | Issued |
Array
(
[id] => 7488764
[patent_doc_number] => 08029786
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-10-04
[patent_title] => 'Antibodies against a peptide epitope of apolipoprotein B'
[patent_app_type] => utility
[patent_app_number] => 12/394886
[patent_app_country] => US
[patent_app_date] => 2009-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 11471
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/029/08029786.pdf
[firstpage_image] =>[orig_patent_app_number] => 12394886
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/394886 | Antibodies against a peptide epitope of apolipoprotein B | Feb 26, 2009 | Issued |
Array
(
[id] => 5434979
[patent_doc_number] => 20090169565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-07-02
[patent_title] => 'NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF'
[patent_app_type] => utility
[patent_app_number] => 12/393693
[patent_app_country] => US
[patent_app_date] => 2009-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 162791
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0169/20090169565.pdf
[firstpage_image] =>[orig_patent_app_number] => 12393693
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/393693 | Neutrokine-alpha antibodies and methods of use thereof | Feb 25, 2009 | Issued |
Array
(
[id] => 5391135
[patent_doc_number] => 20090208448
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-20
[patent_title] => 'Inhibition of angiogenesis'
[patent_app_type] => utility
[patent_app_number] => 12/378209
[patent_app_country] => US
[patent_app_date] => 2009-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 9411
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0208/20090208448.pdf
[firstpage_image] =>[orig_patent_app_number] => 12378209
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/378209 | Inhibition of angiogenesis | Feb 11, 2009 | Abandoned |
Array
(
[id] => 9008950
[patent_doc_number] => 08524244
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-09-03
[patent_title] => 'Targeted therapeutics based on engineered proteins that bind EGFR'
[patent_app_type] => utility
[patent_app_number] => 12/867406
[patent_app_country] => US
[patent_app_date] => 2009-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 15
[patent_no_of_words] => 31344
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12867406
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/867406 | Targeted therapeutics based on engineered proteins that bind EGFR | Feb 9, 2009 | Issued |